#$%^&*AU2010238573B220121213.pdf#####Solid Pharmaceutical Dosage Form Abstract A solid pharmaceutical dosage form providing improved oral bioavailability is disclosed for inhibitors of HIV protease. In particular, the dosage form comprises a solid s dispersion of at least one HIV protease inhibitor and at least one pharmaceutically acceptable water-soluble polymer and at least one pharmaceutically acceptable surfactant, said pharmaceutically acceptable water-soluble polymer having a Tg of at least about 50*C. Preferably, the pharmaceutically acceptable surfactant has an HLB value of from about 4 to about 10.
